39 Results for "

c-Raf kinase

" in MedChemExpress (MCE) Product Catalog:
Products (39)

39 Results for "c-Raf kinase" in MCE Product Catalog:

104
104 Publications Verification
Art. -Nr.: HY-12057
CAS. Nr.: 918504-65-1
Reinheit:  99.85%
Synonyms: PLX4032; RG7204; RO5185426
Target:  

Raf Autophagy

Forschungsgebiete:  

Cancer

Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAF V600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .
loading...
    loading...
83
83 Cited Publications
Art. -Nr.: HY-14660A
CAS. Nr.: 1195768-06-9
Reinheit:  99.95%
Synonyms: GSK2118436 Mesylate; GSK 2118436B
Target:  

Raf

Forschungsgebiete:  

Cancer

Dabrafenib Mesylate is a potent and selective Raf kinase inhibitor with IC50s of 0.6 and 5.0 nM for Raf V600E and c-Raf, respectively.
loading...
    loading...
12
12 Cited Publications
Art. -Nr.: HY-11004
CAS. Nr.: 878739-06-1
Reinheit:  99.44%
Target:  

Raf Apoptosis

Forschungsgebiete:  

Cancer

AZ 628 is a pan-Raf kinase inhibitor with IC50s of 105, 34 and 29 nM for B-Raf, B-RafV600E, and c-Raf-1, respectively.
loading...
    loading...
9
9 Cited Publications
Art. -Nr.: HY-10966
CAS. Nr.: 405554-55-4
Reinheit:  99.77%
Target:  

Raf Apoptosis

SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .
loading...
    loading...
9
9 Cited Publications
Art. -Nr.: HY-11010
CAS. Nr.: 345987-15-7
Reinheit:  98.19%
Target:  

JNK

AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties .
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-14177
CAS. Nr.: 1093100-40-3
Reinheit:  98.03%
Target:  

Raf

Forschungsgebiete:  

Cancer

Raf inhibitor 1 is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-Raf WT, B-Raf V600E, and C-Raf, respectively.
loading...
    loading...
3
3 Cited Publications
Art. -Nr.: HY-14177A
CAS. Nr.: 1191385-19-9
Target:  

Raf

Forschungsgebiete:  

Cancer

B-Raf inhibitor 1 dihydrochloride is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-Raf WT, B-Raf V600E, and C-Raf, respectively.
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-13343
CAS. Nr.: 208260-29-1
Reinheit:  98.03%
Target:  

Raf Apoptosis

Forschungsgebiete:  

Cancer

ZM 336372 is a potent inhibitor of the protein kinase c-Raf. The IC50 value is 0.07 μM in the standard assay, which contains 0.1 mM ATP.
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-P80880
Synonyms: Raf1; Raf; Raf proto-oncogene serine/threonine-protein kinase; Proto-oncogene c-Raf; cRaf; Raf-1

Host:  

Rabbit

Application:  

WB, ICC/IF

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Art. -Nr.: HY-107779
CAS. Nr.: 1392429-79-6
Reinheit:  99.16%
Target:  

Raf

Forschungsgebiete:  

Cancer

BI-882370 is a potent and selective RAF kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase. BI-882370 (BI 882370) inhibits the oncogenic BRAF V600E-mutant, the WT BRAF and CRAF kinases with IC50s of 0.4, 0.8, and 0.6 nM, respectively. BI-882370 also inhibits SRC family kinases .
loading...
    loading...
Art. -Nr.: HY-117273
CAS. Nr.: 942507-42-8
Reinheit:  99.77%
Target:  

Raf Autophagy

Forschungsgebiete:  

Cancer

AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC50s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC50, 6 nM), CSF1R (IC50, 35 nM). Anti-tumor activity .
loading...
    loading...
Art. -Nr.: HY-146303
CAS. Nr.: 2770957-08-7
Target:  

Raf

Forschungsgebiete:  

Cancer

C-RAF kinase-IN-1 (compound 1l) is a potent inhibitor of C-RAF kinase with an IC50 of 0.193 μM. C-RAF kinase-IN-1 is a quinoline derivative. C-RAF kinase-IN-1 has the potential for the research of cancer diseases .
loading...
    loading...
Art. -Nr.: HY-126298
CAS. Nr.: 2340020-82-6
Target:  

Raf

Forschungsgebiete:  

Cancer

RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAF V600E and B-RAF WT, respectively .
loading...
    loading...
Art. -Nr.: HY-147125
CAS. Nr.: 2640292-37-9
Target:  

HSP Akt CDK Raf Apoptosis

Forschungsgebiete:  

Cancer

DDO-6600 is a covalent Hsp90 inhibitor. DDO-6600 disrupts the interaction between Hsp90 and its co-chaperone protein Cdc37, thereby inducing the degradation of kinase client proteins (such as AKT, CDK4, c-Raf). DDO-6600 has inhibitory activity against various cancer cells. DDO-6600 inhibits the migration and invasion of HCT-116 cells, and induces cell cycle arrest and apoptosis. DDO-6600 significantly inhibits tumor growth in the HCT-116 xenograft tumor model. DDO-6600 can be used for research on colorectal cancer .
loading...
    loading...
Art. -Nr.: HY-19343
CAS. Nr.: 870603-16-0
Synonyms: BMS-908662
Target:  

Raf

Forschungsgebiete:  

Cancer

XL-281 (BMS-908662) is an orally active inhibitor for RAF kinase, with IC50s of 2.6, 4.5 and 6 nM, for CRAF, B-RAF, and B-RAFV600E, respectively. XL-281 exhibits antitumor activity .
loading...
    loading...
Art. -Nr.: HY-18652A
CAS. Nr.: 946128-90-1
Synonyms: Ro 5126766 potassium; CH5126766 potassium
Target:  

Raf MEK

Forschungsgebiete:  

Cancer

Avutometinib (CH5126766) (potassium) is a RAF/MEK clamp that potently inhibits RAF/MEK kinase activity and induces dominant negative RAF-MEK complexes preventing phosphorylation of MEK by ARAF, BRAF and CRAF. Avutometinib (potassium) shows anti-proliferative potency across tumor cell lines carrying KRAS mutations including PDAC cell lines. Avutometinib (potassium) induces tumor inhibition and increases survival in a KRAS/p53 pancreatic cancer mouse model. Avutometinib (potassium) is promising for research of low-grade-serous-ovarian-carcinoma (LGSOC), ovarian cancer and pancreatic ductal adenocarcinoma (PDAC) .
loading...
    loading...
Art. -Nr.: HY-14660AR
CAS. Nr.: 1195768-06-9
Synonyms: GSK2118436 Mesylate (Standard); GSK 2118436B (Standard)
Target:  

Raf Reference Standards

Forschungsgebiete:  

Cancer

Dabrafenib (Mesylate) (Standard) is the analytical standard of Dabrafenib (Mesylate). This product is intended for research and analytical applications. Dabrafenib Mesylate is a potent and selective Raf kinase inhibitor with IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively.
loading...
    loading...
Art. -Nr.: HY-18817
CAS. Nr.: 228400-22-4
Target:  

Bcr-Abl FGFR Raf RET VEGFR

Forschungsgebiete:  

Cancer

AFG210 is a potent multi-target kinase inhibitor that primarily inhibits Abl kinase (IC50=330 nM), and also has inhibitory effects on other kinases such as B-Raf, C-Raf, FGFR-1, RET and VEGF receptors. AFG210 can be used to study chronic myeloid leukemia and other diseases with abnormal activation of Abl kinase .
loading...
    loading...
Art. -Nr.: HY-12057S
CAS. Nr.: 1365986-90-8
Vemurafenib-d5 is the deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .
loading...
    loading...
Art. -Nr.: HY-12057S1
CAS. Nr.: 1365986-73-7
Synonyms: PLX4032-d7; RG7204-d7; RO5185426-d7
Vemurafenib-d7 is deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .
loading...
    loading...